drugset / Trial / NCT00939588

Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients

NCT00939588

Phase 2 Completed 88 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindBasic science

Summary

This study is designed as a mechanistic study to compare the effect of two different combinations of anti-hypertensive treatments (aliskiren and valsartan vs. telmisartan and ramipril) on the renin-angiotensin-aldosterone system (RAAS) in patients with moderate hypertension.

Timeline

Start
2009-07
Primary completion
2009-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg
Comparator Ramipril Small molecule 10 mg
Comparator Telmisartan Other / unclassified 80 mg
Subject Valsartan Small molecule 320 mg

Indications